{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:36Z","timestamp":1707524316872},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,11]]},"DOI":"10.7759\/cureus.15606","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T02:08:58Z","timestamp":1623463738000},"source":"Crossref","is-referenced-by-count":3,"title":["Mediastinal Low-Grade Fibromyxoid Sarcoma With FUS-CREB3L2 Gene Fusion"],"prefix":"10.7759","author":[{"given":"Chelsey M","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2020.36.131.18668","article-title":"Sclerosing epithelioid fibrosarcoma: rare and serious","volume":"36","author":"Yahyaoui M","year":"2020","unstructured":"Yahyaoui M, Benhammou M, Aharram S, Amghar J, Sadougui M, Agoumi O, Daoudi A. Sclerosing epithelioid fibrosarcoma: rare and serious. Pan Afr Med J. 2020, 36:131. 10.11604\/pamj.2020.36.131.18668","journal-title":"Pan Afr Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0012-4","article-title":"Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours","volume":"15","author":"Dufresne A","year":"2018","unstructured":"Dufresne A, Brahmi M, Karanian M, Blay JY. Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. Nat Rev Clin Oncol. 2018, 15:443-458. 10.1038\/s41571-018-0012-4","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.26","article-title":"Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies","volume":"11","author":"Linch M","year":"2014","unstructured":"Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol. 2014, 11:187-202. 10.1038\/nrclinonc.2014.26","journal-title":"Nat Rev Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/88.5.615","article-title":"Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance","volume":"88","author":"Evans HL","year":"1987","unstructured":"Evans HL. Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol. 1987, 88:615-619. 10.1093\/ajcp\/88.5.615","journal-title":"Am J Clin Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg237","article-title":"Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma","volume":"12","author":"Storlazzi CT","year":"2003","unstructured":"Storlazzi CT, Mertens F, Nascimento A, et al.. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet. 2003, 12:2349-2358. 10.1093\/hmg\/ddg237","journal-title":"Hum Mol Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02605-4","article-title":"Low-grade fibromyxoid sarcoma incidentally discovered as an asymptomatic mediastinal mass: a case report and review of the\u00a0literature","volume":"15","author":"Sajid MI","year":"2021","unstructured":"Sajid MI, Arshad S, Abdul-Ghafar J, Fatimi SH, Din NU. Low-grade fibromyxoid sarcoma incidentally discovered as an asymptomatic mediastinal mass: a case report and review of the\u00a0literature. J Med Case Rep. 2021, 15:50. 10.1186\/s13256-020-02605-4","journal-title":"J Med Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001559","article-title":"Sclerosing epithelioid fibrosarcoma: a distinct sarcoma with aggressive features","volume":"45","author":"Warmke LM","year":"2021","unstructured":"Warmke LM, Meis JM. Sclerosing epithelioid fibrosarcoma: a distinct sarcoma with aggressive features. Am J Surg Pathol. 2021, 45:317-328. 10.1097\/PAS.0000000000001559","journal-title":"Am J Surg Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199509000-00001","article-title":"Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma","volume":"19","author":"Meis-Kindblom JM","year":"1995","unstructured":"Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol. 1995, 19:979-993. 10.1097\/00000478-199509000-00001","journal-title":"Am J Surg Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jasc.2020.05.005","article-title":"Sclerosing epithelioid fibrosarcoma: cytologic characterization with histologic, immunohistologic, molecular, and clinical correlation of 8 cases","volume":"9","author":"Porteus C","year":"2020","unstructured":"Porteus C, Gan Q, Gong Y, et al.. Sclerosing epithelioid fibrosarcoma: cytologic characterization with histologic, immunohistologic, molecular, and clinical correlation of 8 cases. J Am Soc Cytopathol. 2020, 9:513-519. 10.1016\/j.jasc.2020.05.005","journal-title":"J Am Soc Cytopathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3180321959","article-title":"Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group","volume":"31","author":"Guillou L","year":"2007","unstructured":"Guillou L, Benhattar J, Gengler C, et al.. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol. 2007, 31:1387-1402. 10.1097\/PAS.0b013e3180321959","journal-title":"Am J Surg Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000158","article-title":"Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma","volume":"38","author":"Arbajian E","year":"2014","unstructured":"Arbajian E, Puls F, Magnusson L, et al.. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2014, 38:801-808. 10.1097\/PAS.0000000000000158","journal-title":"Am J Surg Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.04.010","article-title":"Hybrid sclerosing epithelioid fibrosarcoma\/low grade fibromyxoid sarcoma arising in the small intestine with distinct HEY1-NCOA2 gene fusion","volume":"52","author":"Murshed KA","year":"2020","unstructured":"Murshed KA, Ammar A. Hybrid sclerosing epithelioid fibrosarcoma\/low grade fibromyxoid sarcoma arising in the small intestine with distinct HEY1-NCOA2 gene fusion. Pathology. 2020, 52:607-610. 10.1016\/j.pathol.2020.04.010","journal-title":"Pathology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. The","volume":"21","author":"Gounder M","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, et al.. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. The. Lancet Oncol. 2020, 21:1423-1432. 10.1016\/s1470-2045(20)30451-4","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-189112000-00015","article-title":"II. Contribution to the knowledge of sarcoma","volume":"14","author":"Coley WB","year":"1891","unstructured":"Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. 1891, 14:199-220. 10.1097\/00000658-189112000-00015","journal-title":"Ann Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo SP","year":"2018","unstructured":"D'Angelo SP, Mahoney MR, Van Tine BA, et al.. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018, 19:416-426. 10.1016\/S1470-2045(18)30006-8","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi HA","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al.. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017, 18:1493-1501. 10.1016\/S1470-2045(17)30624-1","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00201","article-title":"Clinical benefit from immune checkpoint blockade in sclerosing epithelioid fibrosarcoma: a translocation-associated sarcoma","volume":"5","author":"Doshi SD","year":"2021","unstructured":"Doshi SD, Oza J, Remotti H, Remotti F, Moy MP, Schwartz GK, Ingham M. Clinical benefit from immune checkpoint blockade in sclerosing epithelioid fibrosarcoma: a translocation-associated sarcoma. JCO Precision Oncol. 2021, 5:1-5. 10.1200\/po.20.00201","journal-title":"JCO Precision Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000332","article-title":"Rapid and complete response to combination anti-CTLA-4 and anti-PD-1 checkpoint inhibitor therapy in a patient with stage IV refractory end-stage epithelioid sarcoma: a case report","volume":"43","author":"Pecora A","year":"2020","unstructured":"Pecora A, Halpern S, Weber M, Paleoudis EG, Panush D, Patterson F, Toretsky J. Rapid and complete response to combination anti-CTLA-4 and anti-PD-1 checkpoint inhibitor therapy in a patient with stage IV refractory end-stage epithelioid sarcoma: a case report. J Immunother. 2020, 43:286-290. 10.1097\/CJI.0000000000000332","journal-title":"J Immunother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1856","article-title":"In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets","volume":"23","author":"Arbajian E","year":"2017","unstructured":"Arbajian E, Puls F, Antonescu CR, et al.. In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. Clin Cancer Res. 2017, 23:7426-7434. 10.1158\/1078-0432.CCR-17-1856","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/59562-mediastinal-low-grade-fibromyxoid-sarcoma-with-fus-creb3l2-gene-fusion","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:29Z","timestamp":1707506669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/59562-mediastinal-low-grade-fibromyxoid-sarcoma-with-fus-creb3l2-gene-fusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.15606","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}